On 10 June 2026, Gedeon Richter and Indian-headquartered Hetero Labs announced that they have entered a global collaboration agreement to jointly develop, register and commercialise a generic semaglutide injection, referencing Novo Nordisk’s Ozempic®. The companies are intending to submit EU and US regulatory filings in 2027.
The collaboration aims to take advantage of Hetero’s market reach in the US and emerging markets and Richter’s commercial infrastructure across Europe and Central Asia, while retaining the option for Richter to manufacture in Europe in future.
Numerous generic semaglutide products launched on the Indian market in March 2026, including by Dr Reddy’s Zydus, Alkem, Sun Pharma and Glenmark, following expiry of Novo Nordisk’s core Indian patent for semaglutide. Generic semaglutide products were launched in Canada in May 2026 by Apotex and Dr Reddy’s. Apotex received the first US FDA Tentative Approval for its generic semaglutide ANDA in April 2026, giving it an opportunity to be one of the first to launch generic Ozempic® in the US following expiry of Novo Nordisk’s exclusivity/patents.